TRIMU-5, a μ2-opioid receptor agonist, stimulates the hypothalamo-pituitary-adrenal axis

  title={TRIMU-5, a $\mu$2-opioid receptor agonist, stimulates the hypothalamo-pituitary-adrenal axis},
  author={Richard M. Eisenberg},
  journal={Pharmacology Biochemistry and Behavior},
  • R. Eisenberg
  • Published 1 April 1994
  • Biology, Medicine
  • Pharmacology Biochemistry and Behavior

Cyclic endomorphin analogs in targeting opioid receptors to achieve pain relief.

Recent advances in obtaining endomorphin-based cyclic peptide analogs are summarized and cyclization can be viewed as an interesting option.

Effects of prenatal morphine on hypothalamic metabolism of neurotransmitters and gonadal and adrenal activities, during the early postnatal period in the rat

Investigation in newborn rats of the effects of prenatal morphine-exposure on the hypothalamic metabolism of norepinephrine, serotonin and neuropeptide Y and the activity of the hypothalamo-pituitary gonadal and adrenal axes found changes observed on hypothalamic metabolisms are temporally correlated with the early postnatal activation of the corticostimulating function in neonates of both sexes.



DAMGO stimulates the hypothalamo-pituitary-adrenal axis through a mu-2 opioid receptor.

  • R. Eisenberg
  • Biology, Medicine
    The Journal of pharmacology and experimental therapeutics
  • 1993
DAMGO, a highly selective mu opioid agonist, is capable of stimulating the hypothalamo-pituitary-adrenal (HPA) axis to produce a dose-related elevation in plasma corticosterone (CS), and which of the mu receptors was involved using naloxonazine, a mu-1 receptor-selective antagonist was confirmed.

Effects of selective opioid-receptor blockade on the hypothalamo-pituitary-adrenocortical responses to surgical trauma in the rat.

The results suggest that mu- and kappa-opioid receptors mediate opposing actions of endogenous opioid peptides, both of which may be physiologically important in the regulation of CRF release.

Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.

  • R. Eisenberg
  • Biology, Medicine
    The Journal of pharmacology and experimental therapeutics
  • 1985
Data support the notion that stimulation of several subclasses of opiate receptors will result in the activation of the hypothalamo-pituitary-adrenal axis and appear that the mu opiate receptor is involved in the initiation of acute opiate dependence.

Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.

Systemic injections of opiate agonists were made in male rats to elucidate the involvement of multiple opioid receptors in the stress response, confirming a mu and delta opioid input into the hypothalamic-pituitary-adrenocortical axis.

mu-receptor mediates elevated glucose and corticosterone after third ventricle injection of opioid peptides.

Results imply that mu-opioid binding sites previously identified in central autonomic regions may be involved in the regulation of circulating glucose and corticosterone.